Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 15/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10411484 | 0.89 | PTPRB (0.55) | PTPRBALDH1A1LMNATP53MAPT | |
| SCHEMBL17297218 | 0.89 | PTPRB (0.55) | PTPRBALDH1A1LMNATP53MAPT | |
| SCHEMBL19258117 | 0.86 | CCR3 (0.59) | PTPRBCCR3LMNAMAPTHTT | |
| SCHEMBL19258120 | 0.86 | CCR3 (0.59) | PTPRBCCR3LMNAMAPTHTT | |
| SCHEMBL19257972 | 0.86 | CCR3 (0.59) | PTPRBCCR3LMNAMAPTHTT | |
| SCHEMBL792620 | 0.83 | PTPN1 (0.56) | PTPRBALDH1A1LMNATP53MAPT | |
| SCHEMBL14572899 | 0.83 | PTPN1 (0.56) | PTPRBALDH1A1LMNATP53MAPT | |
| SCHEMBL20586742 | 0.82 | CCR3 (0.47) | PTPRBCCR3LMNAPKMRAB9A | |
| SCHEMBL19209330 | 0.82 | CCR3 (0.47) | PTPRBCCR3LMNAPKMRAB9A | |
| SCHEMBL1206317 | 0.78 | PTPRB (0.41) | PTPRBALDH1A1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190091345-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | HANGZHOU ADCORIS BIOPHARMA CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| WO-2017134547-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091345-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | ERBB2, EGFR, ERBB3 | PTPRB 409/4885CCR3 2194/4885ALDH1A1 2915/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | PTPRB 794/4885CCR3 913/4885ALDH1A1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.